What Can You Expect In 2026?
As pharma and biotech innovation accelerates into 2026, new modalities such as radiopharmaceuticals, antibody-drug conjugates, cell and gene therapies, and vaccines are transforming how drugs are developed and manufactured. With these advances come new safety, sustainability, and compliance challenges that demand smarter, scalable EHS strategies to protect people while enabling innovation.
Featuring expert speakers returning to Boston, the 3rd Annual EHS in Biopharma Summit is the only industry-focused event dedicated exclusively to EHS in biopharma. Bringing together over 100 senior leaders from pharma, biotech, CDMOs, and CROs, this year’s meeting will explore how to derisk next-generation facilities, strengthen safety culture, leverage AI and automation for predictive risk management, and align environmental goals with operational excellence. Featuring expert speakers from AbbVie, AstraZeneca, Charles River Laboratories, Sanofi, Genentech, The Jackson Laboratory, and Ultragenyx, the summit delivers the insight, collaboration, and inspiration EHS professionals need to meet the demands of a rapidly evolving biopharma landscape.
Unmissable Event Highlights
AI-Driven Safety Transformation: From Insight to Action
Explore how leading pharma and biotech companies are leveraging automation and AI to predict incidents, streamline compliance, and retain institutional knowledge. These sessions aim to bridge the gap between digital transformation and human oversight, featuring case studies and collaboration with Amgen, Thermo Fisher Scientific, and Zoetis.
Bridging the EHS Talent Gap in Biopharma
As EHS complexity grows with new modalities, the industry faces a critical shortage of skilled professionals. Learn from Pfizer, Sanofi, and Intellia Therapeutics as they share how they’re modernising training, building engagement, and turning compliance learning into true behavioural change.
Human-Centred Safety & Mental Health Integration
Discover how companies like AstraZeneca, Amgen, Ultragenyx, and Jackson Labs are redefining wellbeing - from ergonomic innovation and musculoskeletal disorder prevention to embedding psychological safety at every level of biopharma operations.
From Unknowns to Controls: Managing Risk in Emerging Modalities
Unpack the evolving risk frameworks for radiopharmaceuticals, ADCs, and novel biologics with experts from Sanofi, MannKind Corporation, and AbbVie. Gain insight into balancing unknown toxicology data, regulatory uncertainty, and practical containment design in real R&D and manufacturing settings.
Building Sustainable Biopharma Labs & Contractor Collaboration
Learn how Lab Central and Repligen are future-proofing facilities through adaptive design, unified contractor management, and responsible supply chain safety. Hear how flexible, ergonomic, and low-carbon labs are reshaping the future of safe, sustainable science.
Climate Action in High-Energy Environments
Tackle the toughest challenge in biopharma sustainability – decarbonising 24/7 operations. Learn practical pathways to reduce emissions, align with ISO standards, and translate ESG commitments into operational impact with Biogen.
Attending Companies Include